ClinicalTrials.gov Search Results 01/10/2019

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT00363298	Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD Study Documents:	Title Acronym: Other Ids: 97134	Completed	•Obsessive-Compulsive Disorder	•Drug: dextro-amphetamine •Drug: Sham Comparison	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2 •Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score	Enrollment: 24 Age: 18 Years to 55 Years (Adult) Sex: All	•Stanford University •Obsessive Compulsive Foundation	•Other	Study Start: August 2006 Primary Completion: March 2008 Study Completion: March 2008 First Posted: August 15, 2006 Results First Posted: March 28, 2017 Last Update Posted: March 28, 2017	•Stanford University School of Medicine, Stanford, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
2	NCT02668926	Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine. Study Documents:	Title Acronym: LisDex Other Ids: EKNZ 2015-00015	Completed	•Healthy	•Drug: Lisdexamfetamine, d-amphetamine, Placebo •Drug: d-amphetamine, Placebo, Lisdexamfetamine •Drug: Placebo, Lisdexamfetamine, d-amphetamine	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: •Effects of lisdexamphetamine and d-Amphetamine on circulating steroidal hormones •Subjective effects of lisdexamphetamine and d-amphetamine •Effects of lisdexamphetamine and d-Amphetamine on emotion recognition and empathy	Enrollment: 24 Age: 18 Years to 45 Years (Adult) Sex: All	•University Hospital, Basel, Switzerland	•Other	Study Start: May 2016 Primary Completion: June 2016 Study Completion: December 2016 First Posted: January 29, 2016 Results First Posted: No Results Posted Last Update Posted: December 11, 2018	•University Hospital Basel, Basel, Basel Stadt, Switzerland
3	NCT01711021	Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children & Adolescents With ADHD Study Documents:	Title Acronym: Other Ids: N25-006	Completed	•Attention Deficit Hyperactivity Disorder	•Drug: d-Amphetamine Transdermal System •Drug: Placebo patch	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: Change from baseline in total SKAMP Scores	Enrollment: 106 Age: 6 Years to 17 Years (Child) Sex: All	•Noven Pharmaceuticals, Inc.	•Industry	Study Start: October 2012 Primary Completion: March 2013 Study Completion: March 2013 First Posted: October 22, 2012 Results First Posted: No Results Posted Last Update Posted: November 5, 2015	•Center for Children and Families, Miami, Florida, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT03369015	Effect of D-amphetamine on Reward Functioning Study Documents:	Title Acronym: Other Ids: HSC-MS-17-0604	Recruiting	•Anhedonia	•Drug: 10 mg d-amphetamine •Drug: 20mg d-amphetamine •Drug: Placebo	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Participant) •Primary Purpose: Basic Science Outcome Measures: •Reward motivation as assessed by the Effort Expenditure for Reward Task (EEfRT) •Reward learning as assessed by the Probabilistic Reward Task (PRT) •Reward learning as assessed by the Effort Learning Task (ELT) •Level of influence of counterfactual information on later decision-making, as measured by the Counterfactual Gambling Task (CGT) •Mood state as assessed by the Profile of Mood States (POMS) •Subjective effects of drug as assessed by the Drug Effects Questionnaire (DEQ)	Enrollment: 30 Age: 18 Years to 35 Years (Adult) Sex: All	•The University of Texas Health Science Center, Houston •Emory University	•Other	Study Start: January 24, 2018 Primary Completion: November 1, 2018 Study Completion: November 1, 2018 First Posted: December 11, 2017 Results First Posted: No Results Posted Last Update Posted: July 16, 2018	•The University of Texas Health Science Center at Houston, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
5	NCT02383043	Impact of Sustained Released-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer Study Documents:	Title Acronym: Other Ids: R01DA033364-02	Completed	•Active Cocaine Users	•Drug: Cocaine •Drug: Sustained Release d-Amphetamine	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: Number of Injections of self-administered cocaine	Enrollment: 16 Age: 21 Years to 45 Years (Adult) Sex: All	•Joshua A. Lile, Ph.D. •University of Kentucky	•Other	Study Start: February 1, 2015 Primary Completion: April 5, 2018 Study Completion: April 5, 2018 First Posted: March 9, 2015 Results First Posted: No Results Posted Last Update Posted: October 10, 2018	•Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
6	NCT01905371	Amphetamine-Enhanced Stroke Recovery Study Documents:	Title Acronym: Other Ids: Pro00044966	Completed	•Stroke	•Drug: Dextroamphetamine •Other: Physical Therapy •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Mean Change in Fugl-Meyer Score from Baseline to 90 days Poststroke •Mean Change in Ambulation Speed Score from Baseline to 90 Days Poststroke •Mean Change in Ambulation Endurance Score from Baseline to 90 days Poststroke •Mean Change in the Action Research Arm Test (ARAT) score from Baseline to 90 days Poststroke •Mean Change in the Mobility Subscale of the Functional Independence Measure from Baseline •Mean Change in the NIH Stroke Scale Score from Baseline •Mean Change in Rankin Scale Score from Baseline •Mean Change in Mini-Mental State Examination Score	Enrollment: 99 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Duke University	•Other	Study Start: April 2001 Primary Completion: June 2007 Study Completion: June 2007 First Posted: July 23, 2013 Results First Posted: No Results Posted Last Update Posted: July 23, 2013	•Duke University Medical Center, Durham, North Carolina, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT00218348	Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Study Documents:	Title Acronym: Other Ids: •NIDA-16305-1 •R01DA016305 •R01-16305-1 •DPMC	Completed	•Cocaine-Related Disorders	•Drug: Dextro-Amphetamine Sulfate	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •Substance use and retention •Effectiveness measures, including psycho-social variables, side effects, and self-reported measures	Enrollment: 186 Age: 25 Years to 50 Years (Adult) Sex: All	•The University of Texas Health Science Center, Houston •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: September 2003 Primary Completion: November 2007 Study Completion: November 2007 First Posted: September 22, 2005 Results First Posted: No Results Posted Last Update Posted: December 19, 2017	•The University of Texas Health Science Center at Houston, Houston, Texas, United States
8	NCT03200080	A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Study Documents:	Title Acronym: Other Ids: TOZ-CL09	Terminated	•Abuse Potential	•Drug: Tozadenant •Drug: Placebo oral tablet •Drug: d-amphetamine •Drug: Placebo oral capsule	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Other Outcome Measures: •Drug Liking •Balance of effects •Global effects •Positive drug effects •Negative drug effects •Stimulant effects •Other drug effects: •Cognitive and psychomotor effects	Enrollment: 26 Age: 18 Years to 55 Years (Adult) Sex: All	•Biotie Therapies Inc. •Acorda Therapeutics	•Industry	Study Start: September 18, 2017 Primary Completion: November 28, 2017 Study Completion: November 28, 2017 First Posted: June 27, 2017 Results First Posted: No Results Posted Last Update Posted: August 13, 2018	•INC Research Toronto, Inc., Toronto, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT00000308	Dextroamphetamine-Cocaine Behavioral Intervention - 5 Study Documents:	Title Acronym: Other Ids: •NIDA-09262-5 •P50-09262-5	Completed	•Cocaine-Related Disorders	•Drug: Dextroamphetamine •Drug: D-amphetamine •Drug: placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Verifiable cocaine abstinence	Enrollment: 54 Age: 18 Years to 45 Years (Adult) Sex: All	•National Institute on Drug Abuse (NIDA) •University of Texas	•NIH •Other	Study Start: September 1995 Primary Completion: September 2000 Study Completion: September 2000 First Posted: September 21, 1999 Results First Posted: No Results Posted Last Update Posted: January 12, 2017	•University of Texas Health Science Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
10	NCT02773212	Targeting Anhedonia in Cocaine Use Disorder Study Documents:	Title Acronym: Other Ids: 2018-0827	Recruiting	•Cocaine-Related Disorders •Anhedonia	•Drug: d-amphetamine •Behavioral: Contingency management •Drug: Placebo (for d-amphetamine)	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Number of Participants who were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) •Change in Consummatory Reward Composite (Anhedonia) •Change in Motivational Reward Composite (Anhedonia) •Change in Reward Learning Composite (Anhedonia) •Treatment Effectiveness Score •Consummatory Reward as Assessed by The Emotional Picture Rating Task (EPRT) •Motivational Reward as Assessed by the Emotional Picture Keypress Task (EPKT) •Motivational Reward as Assessed by the Effort Expenditure for Rewards Task (EEfRT) •Consummatory Reward as Assessed by the Snaith-Hamilton Pleasure Scale (SHAPS) Score •Consummatory Reward as Assessed by the Temporal Experience of Pleasure Scale (TEPS) •and 13 more	Enrollment: 80 Age: 18 Years to 60 Years (Adult) Sex: All	•University of Illinois at Chicago •The University of Texas Health Science Center, Houston	•Other	Study Start: February 1, 2017 Primary Completion: April 2021 Study Completion: April 2021 First Posted: May 16, 2016 Results First Posted: No Results Posted Last Update Posted: October 16, 2018	•University of Illinois at Chicago, Chicago, Illinois, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT01215929	Studying Amphetamine Withdrawal in Humans Study Documents:	Title Acronym: Other Ids: 110743	Completed	•Methamphetamine Dependence	•Drug: Dextroamphetamine •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Measure of Methamphetamine Withdrawal	Enrollment: 35 Age: 21 Years to 65 Years (Adult, Older Adult) Sex: All	•University of Arkansas	•Other	Study Start: October 2009 Primary Completion: April 2013 Study Completion: May 2014 First Posted: October 7, 2010 Results First Posted: August 4, 2014 Last Update Posted: August 4, 2014	•University of Arkansas for Medical SCiences, Little Rock, Arkansas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
12	NCT03223844	Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release Study Documents:	Title Acronym: Other Ids: 16969	Recruiting	•Schizophrenia •Psychosis •Sensitisation	•Drug: Dextroamphetamine Sulfate	Study Type: Interventional Phase: Not Applicable Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: •[18F]FDOPA Ki values •[11C]-(+)-PHNO BPND values •Subjective ratings of amphetamine effects (Drug Effects Questionnaire) •Subjective ratings of amphetamine effects (Subjective States Questionnaire) •Cognitive measures •Impulsiveness •Personality-related markers •Peripheral markers of sensitization •Salivary cortisol •Fractional anisotropy (diffusion-weighted tensor imaging) of white matter •Gray matter volume •Functional connectivity	Enrollment: 22 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Medical University of Vienna	•Other	Study Start: January 1, 2018 Primary Completion: August 2021 Study Completion: December 2021 First Posted: July 21, 2017 Results First Posted: No Results Posted Last Update Posted: April 19, 2018	•Medical University of Vienna, Vienna, Austria

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT03772314	Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia Study Documents:	Title Acronym: Other Ids: IRB00108167	Not yet recruiting	•Idiopathic Hypersomnia •Narcolepsy Without Cataplexy	•Drug: Modafinil •Drug: Amphetamine-Dextroamphetamine	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Epworth Sleepiness Scale (ESS) Score •Change in Patient Global Impression of Change (PGIc) for Sleepiness Score •Change in Patient Global Impression of Change (PGIc) for Sleep Inertia Score •Change in Patient Global Impression of Change (PGIc) for Cognitive Dysfunction Score	Enrollment: 44 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Emory University •American Academy of Sleep Medicine	•Other	Study Start: March 2019 Primary Completion: February 2022 Study Completion: February 2022 First Posted: December 11, 2018 Results First Posted: No Results Posted Last Update Posted: December 11, 2018	•Emory Sleep Center, Atlanta, Georgia, United States
14	NCT03616717	Amphetamine Effects on EEG Biomarkers of Reward and Motivation Study Documents:	Title Acronym: Other Ids: 4UH3MH109168-03	Not yet recruiting	•Healthy Adults	•Drug: dextroamphetamine •Drug: placebo	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Other Outcome Measures: •Reward Positivity •Motivation Signal	Enrollment: 23 Age: 18 Years to 35 Years (Adult) Sex: All	•University of California, San Diego	•Other	Study Start: September 1, 2018 Primary Completion: August 31, 2019 Study Completion: August 31, 2019 First Posted: August 6, 2018 Results First Posted: No Results Posted Last Update Posted: August 6, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
15	NCT02634684	Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. Study Documents:	Title Acronym: Other Ids: •5R01MH059803-15 •Eyeblink Study	Recruiting	•Schizophrenia	•Drug: Dextroamphetamine •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Prepulse inhibition (PPI) •MATRICS Consensus Cognitive Battery Performance (MCCB) •Targeted Cognitive Training (TCT): PositScience, Inc.	Enrollment: 160 Age: 18 Years to 55 Years (Adult) Sex: All	•University of California, San Diego	•Other	Study Start: July 2014 Primary Completion: April 2019 Study Completion: December 2020 First Posted: December 18, 2015 Results First Posted: No Results Posted Last Update Posted: May 21, 2018	•Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States
16	NCT00000305	Amphetamine Cocaine Interaction Study - 2 Study Documents:	Title Acronym: Other Ids: •NIDA-09262-2 •P50DA009262 •P50-09262-2	Terminated	•Cocaine-Related Disorders	•Drug: Dextroamphetamine	Study Type: Interventional Phase: Phase 1 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: 0 Age: 18 Years to 45 Years (Adult) Sex: Male	•The University of Texas Health Science Center, Houston •National Institute on Drug Abuse (NIDA) •University of Texas	•Other •NIH	Study Start: Primary Completion: Study Completion: First Posted: September 21, 1999 Results First Posted: No Results Posted Last Update Posted: May 18, 2012	•University of Texas Health Science Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
17	NCT01699607	Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm Study Documents:	Title Acronym: phno_amth Other Ids: 0910005822	Completed	•Nicotine Dependence •Healthy	•Drug: Amphetamine	Study Type: Interventional Phase: Not Applicable Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) Outcome Measures: Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.	Enrollment: 10 Age: 18 Years to 55 Years (Adult) Sex: All	•Yale University	•Other	Study Start: June 2012 Primary Completion: July 2013 Study Completion: July 2013 First Posted: October 3, 2012 Results First Posted: September 18, 2015 Last Update Posted: February 9, 2017	•Yale University, New Haven, Connecticut, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
18	NCT01478113	Stimulant Enhancement of Well-Being Therapy for Depression Study Documents:	Title Acronym: Other Ids: •2011P002148 •2011D002171	Terminated	•Major Depressive Disorder	•Drug: Amphetamine/ dextroamphetamine •Drug: Placebo •Behavioral: Well-being therapy	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Hamilton-Depression Rating Scale(SIGH-D)-17 Items •Change in Hamilton-Depression Rating Scale(SIGH-D)-31 Item •Change in Psychological Well-being Scale (PWB) •Change in the Snaith-Hamilton Pleasure Scale (SHAPS) •Change in Behavioral Inhibition/Activation Scale (BIS/BAS) •Change in Positive and Negative Affective Scale (PANAS) •Change in Functioning on Short Form-12(SF-12)	Enrollment: 5 Age: 18 Years to 60 Years (Adult) Sex: All	•Massachusetts General Hospital •Harvard Medical School	•Other	Study Start: February 2012 Primary Completion: July 2014 Study Completion: July 2015 First Posted: November 23, 2011 Results First Posted: April 26, 2017 Last Update Posted: April 26, 2017	•Depression Clinical and Research Program, Boston, Massachusetts, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
19	NCT01886469	A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) Study Documents:	Title Acronym: Other Ids: •HLD100-102 •HLD100-102 (Control # 163513)	Completed	•Attention-Deficit Hyperactivity Disorder	•Drug: HLD100-B •Drug: HLD100-C •Drug: HLD100-E	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Rate and Extent of absorption of d-amphetamine (AUC0-tz, AUC0-#, Cmax, Tmax, absorption lag time, #z, and t1/2elim) •Safety (AEs, ECG, laboratory parameters, physical examinations)	Enrollment: 22 Age: 6 Years to 17 Years (Child) Sex: All	•Ironshore Pharmaceuticals and Development, Inc	•Other	Study Start: July 2013 Primary Completion: September 2013 Study Completion: September 2013 First Posted: June 26, 2013 Results First Posted: No Results Posted Last Update Posted: October 3, 2014	•Saskatoon Centre for Patient-Oriented Research, Royal University Hospital, Room 5681, C Wing, Saskatoon, Saskatchewan, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
20	NCT00218062	Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals Study Documents:	Title Acronym: Other Ids: •NIDA-09262-12 •P50DA009262-12 •DPMC	Completed	•Cocaine-Related Disorders	•Drug: D-Amphetamine 30mg •Drug: D-Amphetamine 60mg •Drug: Modafinil 200mg •Drug: Modafinil 400mg •Behavioral: Therapy •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment •Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment •Retention as Indicated by the Number of Participants Who Remained in the Study •Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report •Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples	Enrollment: 73 Age: 18 Years to 55 Years (Adult) Sex: All	•The University of Texas Health Science Center, Houston •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: March 2006 Primary Completion: January 2012 Study Completion: January 2012 First Posted: September 22, 2005 Results First Posted: June 21, 2017 Last Update Posted: June 21, 2017	•University of Texas Health Science Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
21	NCT02348385	Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers Study Documents:	Title Acronym: Other Ids: 1106008678	Completed	•Nicotine Dependence	•Drug: Amphetamine	Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: Percent change in binding potential of dopamine release during PET scan post amphetamine administration	Enrollment: 52 Age: 18 Years to 55 Years (Adult) Sex: All	•Yale University	•Other	Study Start: December 2012 Primary Completion: December 2017 Study Completion: December 2017 First Posted: January 28, 2015 Results First Posted: No Results Posted Last Update Posted: December 18, 2018	•Yale University, New Haven, Connecticut, United States
22	NCT03512171	Decision Making Study in Young and Middle-Aged Adults: Part II Study Documents: •Study Protocol and Statistical Analysis Plan	Title Acronym: DND Other Ids: •151088 •AG043458	Completed	•Healthy Adults	•Drug: Dextroamphetamine •Drug: Placebo •Diagnostic Test: [18F]Fallypride •Diagnostic Test: [18F]-FE-PE2I	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Basic Science Outcome Measures: •Dopamine D2 receptor availability (binding potential) •Quantification of Dopamine Transporter Levels •Decision Making Task 1 •Decision Making Task 2 •Cognitive Task 1 (processing speed) •Cognitive Task 2 (verbal fluency) •Cognitive Task 3 •Motor Task 1 •Change in Spontaneous Eye Blink Rate	Enrollment: 65 Age: 20 Years to 65 Years (Adult, Older Adult) Sex: All	•Vanderbilt University •Duke University	•Other	Study Start: March 31, 2016 Primary Completion: May 15, 2018 Study Completion: May 15, 2018 First Posted: April 30, 2018 Results First Posted: No Results Posted Last Update Posted: August 15, 2018	•Zald Affective Neuroscience Lab- Vanderbilt University, Nashville, Tennessee, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
23	NCT00000304	Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 Study Documents:	Title Acronym: Other Ids: •NIDA-09262-1 •P50-09262-1	Completed	•Cocaine-Related Disorders •Substance-Related Disorders	•Drug: Dextroamphetamine •Drug: D-Amphetamine •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: verifiable cocaine abstinence	Enrollment: 120 Age: 18 Years to 45 Years (Adult) Sex: All	•National Institute on Drug Abuse (NIDA) •University of Texas	•NIH •Other	Study Start: August 1997 Primary Completion: August 2001 Study Completion: August 2001 First Posted: September 21, 1999 Results First Posted: No Results Posted Last Update Posted: January 12, 2017	•University of Texas Health Science Center, Houston, Texas, United States
24	NCT03349606	Cocaine Use Disorder and Cortical Dopamine Study Documents:	Title Acronym: Other Ids: •PRO10030625 •R01DA026472 •PRO14080588	Recruiting	•Cocaine Dependence	•Drug: d-amphetamine •Radiation: [C-11]FLB 457	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: Percent change in Binding potential (BPnd)	Enrollment: 30 Age: 18 Years to 40 Years (Adult) Sex: All	•University of Pittsburgh •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: June 2, 2010 Primary Completion: December 31, 2020 Study Completion: December 31, 2020 First Posted: November 21, 2017 Results First Posted: No Results Posted Last Update Posted: September 6, 2018	•University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
25	NCT00429767	Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals Study Documents:	Title Acronym: Other Ids: •NIDA - 022243 •R01DA022243 •DPMCDA	Completed	•Heroin Dependence •Opioid-Related Disorders •Cocaine Abuse or Dependence		Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures:	Enrollment: 16 Age: 18 Years to 55 Years (Adult) Sex: All	•Wayne State University •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: January 2007 Primary Completion: January 2010 Study Completion: January 2010 First Posted: February 1, 2007 Results First Posted: No Results Posted Last Update Posted: June 5, 2012	•Wayne State University, Detroit, Michigan, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
26	NCT02485158	Individual Differences in the Response to Drugs Study Documents:	Title Acronym: TDS Other Ids: IRB13-0534	Completed	•Healthy	•Drug: THC •Drug: AMP •Drug: ALC •Drug: Placebo capsules •Drug: Placebo beverage	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: •Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration •Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration •Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration •Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion •Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration •Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration •Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration •Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration •Change in Specific Drug Effects (Addiction Research Center	Enrollment: 28 Age: 21 Years to 35 Years (Adult) Sex: All	•University of Chicago	•Other	Study Start: July 2013 Primary Completion: December 2013 Study Completion: December 2013 First Posted: June 30, 2015 Results First Posted: November 29, 2016 Last Update Posted: November 29, 2016	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
27	NCT03606473	Brain Mechanisms in Young Adults Study Documents:	Title Acronym: MHP Other Ids: PRO17080203	Recruiting	•Cocaine-Related Disorders	•Drug: d-amphetamine •Radiation: [C-11]NPA	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: Percent change in Binding potential (BPnd)	Enrollment: 30 Age: 25 Years to 30 Years (Adult) Sex: All	•Gale Richardson •National Institute on Drug Abuse (NIDA) •University of Pittsburgh	•Other •NIH	Study Start: January 24, 2018 Primary Completion: January 1, 2022 Study Completion: January 1, 2022 First Posted: July 30, 2018 Results First Posted: No Results Posted Last Update Posted: July 30, 2018	•University of Pittsburgh, Pittsburgh, Pennsylvania, United States
28	NCT00069927	Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression Study Documents:	Title Acronym: Other Ids: •SCUSF 0201 •HLMCC-0201 •U10CA081920 •SCUSF-0201	Terminated	•Depression •Neurotoxicity •Unspecified Childhood Solid Tumor, Protocol Specific	•Drug: Adderall-XR® •Drug: Concerta®	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures: •Response rate as measured by Wechsler Intelligence Scale for Children-III (WISC III) subtest: Coding, Symbol Search and Digit Span at baseline, and 3 weeks after the start of study treatment •Durability of response as measured by WISC III subtest: Coding, Symbol Search and Digit Span at 12 weeks after the start of study treatment •Depression as measured by Children's Depression Inventory Short Version (CDI-S) at baseline, weeks 3 and 12	Enrollment: 12 Age: 6 Years to 17 Years (Child) Sex: All	•University of South Florida •National Cancer Institute (NCI)	•Other •NIH	Study Start: August 2003 Primary Completion: June 2006 Study Completion: September 2006 First Posted: October 7, 2003 Results First Posted: No Results Posted Last Update Posted: February 3, 2014	•University of Florida Shands Cancer Center, Gainesville, Florida, United States •Sacred Heart Children's Hospital, Pensacola, Florida, United States •St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States •CCOP - Florida Pediatric, Tampa, Florida, United States •MBCCOP-Medical College of Georgia Cancer Center, Augusta, Georgia, United States •William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States •Wilford Hall Medical Center, Lackland Air Force Base, Texas, United States •CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States •MBCCOP - South Texas Pediatrics, San Antonio, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
29	NCT02144415	A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users Study Documents:	Title Acronym: Other Ids: EB-1020 IR-103	Completed	•Healthy Volunteers •Drug Users	•Drug: EB-1020 400 mg •Drug: EB-1020 800 mg •Drug: lisdexamfetamine 150 mg •Drug: d-amphetamine 40 mg •Drug: Placebo	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Maximum effect (Emax) on Drug Liking visual analog scale (VAS) •Drug Liking VAS (minimum effect [Emin] and time-averaged area under the effect curve to 12 hours after study drug administration [TA_AUE]) •Overall Drug Liking VAS (Emax/Emin) •Take Drug Again VAS (Emax) •High VAS (Emax and TA_AUE) •Good Effects VAS (Emax and TA_AUE) •Bad Effects VAS (Emax and TA_AUE) •Nausea VAS (Emax and TA_AUE) •ARCI-A scale (Emax and TA_AUE) •ARCI-BG scale (Emax and TA_AUE) •and 8 more	Enrollment: 80 Age: 18 Years to 55 Years (Adult) Sex: Male	•Neurovance, Inc. •Euthymics BioScience, Inc.	•Industry	Study Start: May 2014 Primary Completion: July 2014 Study Completion: July 2014 First Posted: May 22, 2014 Results First Posted: No Results Posted Last Update Posted: August 15, 2014	•Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
30	NCT02203786	D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Study Documents:	Title Acronym: HFDEX Other Ids: 232-2009	Completed	•Pathological Gambling	•Drug: Haloperidol •Drug: Fluphenazine •Drug: Dexedrine •Drug: Placebo •Behavioral: Slot Machine	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Diagnostic Outcome Measures: •Subjective Reinforcement Self-report Scales •Diastolic Blood Pressure (DBP) •Cognitive Task Performance •Betting Behaviour in Laboratory-based Slot Machine Game •Speed of Play on Slot Machine Game •Winnings on Slot Machine Upon Completion of Game	Enrollment: 60 Age: 19 Years to 65 Years (Adult, Older Adult) Sex: All	•Centre for Addiction and Mental Health •Canadian Institutes of Health Research (CIHR)	•Other	Study Start: September 2009 Primary Completion: June 2015 Study Completion: September 2015 First Posted: July 30, 2014 Results First Posted: April 25, 2016 Last Update Posted: April 25, 2016	•Centre for Addiction and Mental Health, Toronto, Ontario, Canada
31	NCT00611936	Effects of Atomoxetine Treatment in Humans Study Documents:	Title Acronym: Other Ids: 0605001441	Completed	•Stress	•Drug: Placebo •Drug: Atomoxetine	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: Measuring subjective responses to physical and psychological models of stress and oral amphetamine in healthy volunteers.	Enrollment: 10 Age: 18 Years to 45 Years (Adult) Sex: All	•Yale University •US Department of Veterans Affairs	•Other •U.S. Fed	Study Start: June 2006 Primary Completion: August 2007 Study Completion: September 2009 First Posted: February 11, 2008 Results First Posted: No Results Posted Last Update Posted: July 25, 2012	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
32	NCT00943930	Marijuana Drug Discrimination and Self-Administration Study Documents:	Title Acronym: DDC Other Ids: •NIDA DA026761 •R01DA026761-01	Completed	•Marijuana Abuse	•Drug: THC (delta-9 tetrahydrocannabinol d-amphetamine, oral THC	Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures: •To test the ability of oral THC to alter the discriminative stimulus and reinforcing effects of smoked marijuana. •Subjective effects: Self-report questionnaires regarding subjective drug effects, craving, withdrawal symptoms, and marijuana choice will be assessed. Physiological effects: Heart rate, skin temperature, and blood pressure will be monitored.	Enrollment: 29 Age: 21 Years to 45 Years (Adult) Sex: All	•Wayne State University •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: April 2009 Primary Completion: December 2012 Study Completion: December 2014 First Posted: July 22, 2009 Results First Posted: No Results Posted Last Update Posted: April 28, 2016	•Wayne State University, Detroit, Michigan, United States
33	NCT02020408	Monoamine Contributions to Neurocircuitry in Eating Disorders Study Documents:	Title Acronym: Other Ids: •090661 •R01MH092793	Completed	•Eating Disorder	•Drug: [11C]raclopride •Drug: [11C]DASB •Drug: amphetamine	Study Type: Interventional Phase: Phase 4 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: •1. 5-HT transporter binding and Dopamine (DA) D2/ D3 binding as measured during the PET scan •Change in [11C]raclopride binding potential from baseline to post-amphetamine administration as measured during the two 90 min PET scans.	Enrollment: 88 Age: 18 Years to 45 Years (Adult) Sex: Female	•University of California, San Diego •National Institute of Mental Health (NIMH)	•Other •NIH	Study Start: May 2011 Primary Completion: April 2016 Study Completion: April 2016 First Posted: December 24, 2013 Results First Posted: No Results Posted Last Update Posted: May 18, 2016	•University of California San Diego, San Diego, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
34	NCT00697138	Agonist Replacement Therapy for Cocaine Dependence Study Documents:	Title Acronym: Other Ids: •DA021155 •Agonists for Cocaine Abuse •R01DA021155 •DPMC	Completed	•Cocaine Dependence	•Drug: d-Amphetamine; Atomoxetine	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Crossover Assignment •Masking: Double (Participant, Care Provider) •Primary Purpose: Basic Science Outcome Measures: •Behavioral effects of cocaine •Heart rate; blood pressure; ECG	Enrollment: 46 Age: 18 Years to 50 Years (Adult) Sex: All	•University of Kentucky •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: June 2006 Primary Completion: January 2012 Study Completion: January 2012 First Posted: June 13, 2008 Results First Posted: No Results Posted Last Update Posted: March 1, 2012	•University of Kentucky Medical Center, Lexington, Kentucky, United States
35	NCT03019822	Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing Study Documents:	Title Acronym: LAM Other Ids: BASEC 2016-01827	Completed	•Healthy	•Drug: LSD •Drug: MDMA •Drug: Amphetamine •Drug: Placebo	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: •Emotional enhancement as determined by fMRI •fMRI brain activity •Resting State fMRI •Effect Modulation by personality traits (assessed with questionnaires), •Effect Modulation by amygdala reactivity to fear (assessed in the fMRI) •Effect Modulation by genetic polymorphisms (determined by genotyping of each subject)	Enrollment: 28 Age: 25 Years to 50 Years (Adult) Sex: All	•University Hospital, Basel, Switzerland	•Other	Study Start: February 1, 2017 Primary Completion: August 11, 2018 Study Completion: September 4, 2018 First Posted: January 13, 2017 Results First Posted: No Results Posted Last Update Posted: October 15, 2018	•University Hospital Basel, Basel, Basel Stadt, Switzerland

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
36	NCT00202605	Safety and Efficacy of SPD465 in Adults With ADHD Study Documents:	Title Acronym: Other Ids: SPD465-203	Completed	•Attention Deficit Disorder With Hyperactivity	•Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,l-amphetamine aspartate monohydrate	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •PERMP (Permanent Product Measure of Performance) at 7 time points •Time Segment Rating System (ADHD-RS[TSRS]) •Subject self report (ADHD-SRS) of ADHD •Treatment emergent adverse events •Modified Pittsburgh Sleep Quality Index (PSQI)	Enrollment: 72 Age: 18 Years to 55 Years (Adult) Sex: All	•Shire	•Industry	Study Start: September 2005 Primary Completion: Study Completion: April 2006 First Posted: September 20, 2005 Results First Posted: No Results Posted Last Update Posted: November 6, 2007	•Clinical Study Center, Little Rock, Arkansas, United States •UCI Child Development Center, Irvine, California, United States •Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States •Bayou City Research, Ltd., Houston, Texas, United States
37	NCT00572767	Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke Study Documents:	Title Acronym: Other Ids: •2000/001 •2000/030	Terminated	•Stroke	•Drug: Dextro-Amphetamin •Other: Glucose	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Chedoke-McMaster Stroke Assessment (motor impairment measure)	Enrollment: 16 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Reha Rheinfelden	•Other	Study Start: January 2001 Primary Completion: Study Completion: September 2006 First Posted: December 13, 2007 Results First Posted: No Results Posted Last Update Posted: December 13, 2007	•Reha Rheinfelden, Rheinfelden, AG, Switzerland

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
38	NCT00150579	Efficacy and Safety of SPD465 in Adults With ADHD Study Documents:	Title Acronym: Other Ids: SPD465-301	Completed	•Attention Deficit Disorder With Hyperactivity	•Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV) taken at the Baseline visit and all visits thereafter. •Clinical Global Impression of Improvement scale (CGI-I) - assessed at visits A1 through A7/Early Termination (ET) •Time-Sensitive ADHD Symptom Scale (TASS) - completed at the Baseline visit and twice daily throughout the remainder of the subjects participation in this study •Brown ADD Scale (BADDS) - completed at the Baseline and A7/ET visits •Adult ADHD Impact Module (AIM-A) - completed at the Baseline and A7/ET visits •Pittsburgh Sleep Quality Index (PSQI) - completed at every visit from Baseline to study completion/ET	Enrollment: 240 Age: 18 Years to 55 Years (Adult) Sex: All	•Shire	•Industry	Study Start: January 2005 Primary Completion: Study Completion: December 2005 First Posted: September 8, 2005 Results First Posted: No Results Posted Last Update Posted: November 6, 2007	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
39	NCT00152035	Safety of SPD465 in Treating Adults With ADHD. Study Documents:	Title Acronym: Other Ids: SPD465-304	Completed	•Attention Deficit Disorder With Hyperactivity	•Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •The evaluation of safety will be based on the occurrence of treatment emergent AEs and specific evaluation of vitals signs, ECG, laboratory and physical examination. •ADHD-rating scale (ADHD-RS-IV) taken at the Visit 1 and all visits thereafter. •Clinical Global Impression of Improvement scale assessed at Visits 1 through 15/Early Termination (ET). •Pittsburgh Sleep Quality Index (PSQI) - assessed at Visits 1 through 15/ET.	Enrollment: 1040 Age: 18 Years to 55 Years (Adult) Sex: All	•Shire	•Industry	Study Start: March 2005 Primary Completion: Study Completion: May 2007 First Posted: September 9, 2005 Results First Posted: No Results Posted Last Update Posted: January 16, 2017	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
40	NCT00152022	Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. Study Documents:	Title Acronym: Other Ids: SPD465-303	Completed	•Attention Deficit Disorder With Hyperactivity	•Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV) taken at the Baseline visit and all visits thereafter. •Clinical Global Impression of Improvement scale (CG(-I) - assessed at visits 1 through 6/Early Termination (ET) •Brown ADD Scale (BADDS) - completed at Baseline and 6/ET visits •Adult ADHD Impact Module (AIM-A)-completed at Baseline and 6/ET visits. •Pittsburgh Sleep Quality Index (PSQI) - taken at every visit from Baseline to study completion.	Enrollment: 412 Age: 18 Years to 55 Years (Adult) Sex: All	•Shire	•Industry	Study Start: April 2005 Primary Completion: Study Completion: April 2006 First Posted: September 9, 2005 Results First Posted: No Results Posted Last Update Posted: January 16, 2017	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
41	NCT03103750	Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD Study Documents:	Title Acronym: Other Ids: •1612018712 •M# 25288	Recruiting	•ADHD	•Procedure: Magnetic Resonance Imaging (MRI) •Drug: Raclopride •Dietary Supplement: calcitriol •Drug: Placebo oral capsule •Procedure: high-resolution research tomography •Drug: Dextro Amphetamine	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •non-displaceable tracer binding potentials •continuous Performance Task (CPT-AX)	Enrollment: 24 Age: 18 Years to 50 Years (Adult) Sex: All	•Yale University •Brain & Behavior Research Foundation	•Other	Study Start: August 15, 2017 Primary Completion: January 2022 Study Completion: January 2022 First Posted: April 6, 2017 Results First Posted: No Results Posted Last Update Posted: January 9, 2019	•Connecticut Mental Health Center, New Haven, Connecticut, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
42	NCT01232361	IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents Study Documents:	Title Acronym: IMPAACT P1080 Other Ids: IMPAACT P1080	Completed	•ADHD •HIV		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Estimation of steady-state oral clearance (Cl/F) for each psychiatric study medication is the primary outcome.	Enrollment: 127 Age: 6 Years to 25 Years (Child, Adult) Sex: All	•International Maternal Pediatric Adolescent AIDS Clinical Trials Group	•Other	Study Start: September 2010 Primary Completion: July 2016 Study Completion: July 2016 First Posted: November 2, 2010 Results First Posted: No Results Posted Last Update Posted: January 23, 2017	•Univ. of Alabama Birmingham NICHD CRS (5096), Birmingham, Alabama, United States •Miller Children's Hospital Long Beach (5093), Long Beach, California, United States •Usc La Nichd Crs (5048), Los Angeles, California, United States •UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601), Los Angeles, California, United States •Univ of California, San Diego (UCSD) (4601), San Diego, California, United States •Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States •Children's National Med. Ctr. Washington DC NICHD CRS (5015), Washington, District of Columbia, United States •South Florida CDC Ft Lauderdale NICHD CRS (5055), Ft Lauderdal, Florida, United States •Univ of Miami Pediatric/ Perinatal HIV/AIDS (4201), Miami, Florida, United States •Chicago Children's CRS (4001), Chicago, Illinois, United States •and 12 more
43	NCT00062946	PET Imaging of Dopamine in Healthy Study Participants Study Documents:	Title Acronym: Other Ids: •030104 •03-M-0104	Completed	•Healthy	•Drug: (18F)fallypride	Study Type: Interventional Phase: Phase 2 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: 45 Age: 18 Years to 45 Years (Adult) Sex: All	•National Institute of Mental Health (NIMH) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: June 17, 2003 Primary Completion: Study Completion: August 15, 2007 First Posted: June 18, 2003 Results First Posted: No Results Posted Last Update Posted: July 2, 2017	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
44	NCT00001783	Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy Study Documents:	Title Acronym: Other Ids: •980115 •98-N-0115	Completed	•Cerebrovascular Accident •Paralysis	•Drug: 0-15 Water	Study Type: Interventional Phase: Phase 2 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: 34 Age: Child, Adult, Older Adult Sex: All	•National Institute of Neurological Disorders and Stroke (NINDS) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: April 1998 Primary Completion: Study Completion: June 2004 First Posted: November 4, 1999 Results First Posted: No Results Posted Last Update Posted: March 4, 2008	•National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
45	NCT00607568	Atomoxetine Effects in Humans Study Documents:	Title Acronym: Other Ids: •MIRECC HIC 0605001441 •K02DA021304 •DPMC	Completed	•Physiological Stress	•Drug: Atomoxetine	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: Atomoxetine treatment, compared to placebo, will attenuate the physiological and subjective responses to stress and d-amphetamine	Enrollment: 10 Age: 18 Years to 45 Years (Adult) Sex: All	•Yale University •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: June 2006 Primary Completion: August 2007 Study Completion: September 2009 First Posted: February 5, 2008 Results First Posted: No Results Posted Last Update Posted: December 12, 2011	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
46	NCT01235338	Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers Study Documents:	Title Acronym: Other Ids: SPD489-117	Completed	•Healthy	•Drug: LDX + Venlafaxine XR •Drug: Venlafaxine XR + LDX	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate •Cmax of d-Amphetamine •Cmax of Venlafaxine Hydrochloride •Cmax of o-Desmethylvenlafaxine •Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine) •Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate •AUC of d-Amphetamine •AUC of Venlafaxine Hydrochloride •AUC of o-Desmethylvenlafaxine •AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine) •and 8 more	Enrollment: 80 Age: 18 Years to 45 Years (Adult) Sex: All	•Shire	•Industry	Study Start: November 2010 Primary Completion: December 2010 Study Completion: January 2011 First Posted: November 5, 2010 Results First Posted: December 8, 2011 Last Update Posted: April 4, 2013	•Clinical Pharmacology of Miami, Miami, Florida, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
47	NCT00698737	Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC) Study Documents:	Title Acronym: ARC Other Ids: •NIDA 022243-2 •R01DA022243 •DPMCDA	Completed	•Heroin Dependence •Opioid-Related Disorders •Cocaine Abuse or Dependence		Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures:	Enrollment: 22 Age: 18 Years to 55 Years (Adult) Sex: All	•Wayne State University •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: April 2008 Primary Completion: November 2012 Study Completion: November 2012 First Posted: June 17, 2008 Results First Posted: No Results Posted Last Update Posted: November 22, 2012	•Wayne State University, Detroit, Michigan, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
48	NCT03327402	Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Study Documents:	Title Acronym: Other Ids: SHP465-112	Completed	•Attention Deficit Hyperactivity Disorder (ADHD)	•Drug: SHP465	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of d- and l-amphetamine •Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Time Point (AUC0-t) of Sample Collection of d- and l-amphetamine •Area Under the Plasma Concentration Versus Time Curve From Time Zero Predose to Five Hours Postdose (AUC0-5) of d- and l-amphetamine •Area Under the Plasma Concentration Versus Time Curve From Time Five Hours to the Last Time Point (AUC5-t) of d- and l-amphetamine •Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of d- and l-amphetamine •Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (24 Hours) at Steady State (AUCtau) of d- and l-amphetamine in Plasma •Total Body Clearance (CL/F) for Extravascular Administration of d- and l-amphetamine •Maximum Concentration (Cmax) Occurring at the Time of Maximum Observed Concentration Sampled During a Dosing	Enrollment: 24 Age: 4 Years to 5 Years (Child) Sex: All	•Shire	•Industry	Study Start: March 13, 2018 Primary Completion: October 5, 2018 Study Completion: October 5, 2018 First Posted: October 31, 2017 Results First Posted: No Results Posted Last Update Posted: January 3, 2019	•Preferred Research Partners, Little Rock, Arkansas, United States •Clinical Neuroscience Solutions Inc, Orlando, Florida, United States •Qualmedica Research, LLC, Evansville, Indiana, United States •University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States •Ohio Pediatric Research Assn Inc, Dayton, Ohio, United States •Professional Psychiatric Services (PPS), Mason, Ohio, United States •Coastal Pediatric Associates, Mount Pleasant, South Carolina, United States •Clinical Neuroscience Solutions Inc, Memphis, Tennessee, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
49	NCT00573859	The Reinforcing Mechanisms of Smoking in Adult ADHD Study Documents:	Title Acronym: Other Ids: •2006-5156 •NIH grant# DA018752	Completed	•ADHD	•Drug: ADHD medication •Drug: Placebo	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Factorial Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Basic Science Outcome Measures: •The Effects of ADHD Medication Versus Placebo on Cotinine Levels •The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission. •The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.	Enrollment: 27 Age: 18 Years to 45 Years (Adult) Sex: All	•University of California, Irvine	•Other	Study Start: September 2006 Primary Completion: June 2010 Study Completion: June 2010 First Posted: December 14, 2007 Results First Posted: November 7, 2011 Last Update Posted: November 7, 2011	•Department of Pediatrics, Irvine, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
50	NCT02478788	Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder Study Documents:	Title Acronym: NERF Other Ids: •DelBello/ McNamara Neuroimaging •R01MH097818-01A	Recruiting	•Attention Deficit Hyperactivity Disorder	•Drug: mixed amphetamine salts-extended release (MAS-XR) •Drug: Placebo	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Other Outcome Measures: •Baseline-endpoint change in prefrontal-amygdala functional connectivity by fMRI. •Baseline-endpoint change in uncinate fasciculus white matter integrity by DTI •Baseline-endpoint change in glutamate (Glu) and N-acetyl aspartate (NAA) concentrations in the prefrontal cortex (BA47) by 1H MRS.	Enrollment: 240 Age: 10 Years to 18 Years (Child, Adult) Sex: All	•University of Cincinnati •National Institute of Mental Health (NIMH)	•Other •NIH	Study Start: November 2015 Primary Completion: August 2020 Study Completion: August 2020 First Posted: June 23, 2015 Results First Posted: No Results Posted Last Update Posted: April 13, 2018	•University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
51	NCT00254033	Apathy Associated With Alzheimer's Disease Study Documents:	Title Acronym: Other Ids: •065-2003 •AHAF Grant Number: A2003-236	Completed	•Dementia •Alzheimer Disease	•Drug: Dextroamphetamine •Drug: Methylphenidate	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •Addiction Research Centre Inventory (ARCI) •Apathy Evaluation Scale-Caregiver (AES-C) •Profile of Mood States (POMS) •Continuous Performance Test (CPT) •Neuropsychiatric Inventory (NPI)	Enrollment: 40 Age: 55 Years and older (Adult, Older Adult) Sex: All	•Sunnybrook Health Sciences Centre •American Health Assistance Foundation	•Other	Study Start: October 2003 Primary Completion: Study Completion: October 2006 First Posted: November 15, 2005 Results First Posted: No Results Posted Last Update Posted: April 28, 2017	•Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
52	NCT02515955	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants Study Documents:	Title Acronym: Other Ids: •CR107762 •54175446EDI1002 •2015-001300-55	Completed	•Healthy	•Drug: JNJ-54175446 •Drug: Minocycline •Drug: JNJ 54175446 Matching Placebo •Drug: D Amphetamine •Drug: D Amphetamine Matching Placebo	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Number of Participants with Adverse Events •Maximum Observed Plasma Concentration (Cmax) •Minimum Observed Plasma Concentration (Cmin) •Trough Plasma Concentration (Ctrough) •Average Plasma Concentration at Steady State (Cavg,ss) •Time to Reach Maximum Observed Plasma Concentration (Tmax) •Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) •Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) •Elimination Half-Life (t1/2)	Enrollment: 76 Age: 18 Years to 55 Years (Adult) Sex: Male	•Janssen-Cilag International NV	•Industry	Study Start: August 2015 Primary Completion: March 2016 Study Completion: March 2016 First Posted: August 5, 2015 Results First Posted: No Results Posted Last Update Posted: June 6, 2016	•Leiden, Netherlands

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
53	NCT00439049	Substance Abuse Pre-Treatment Screening Study Study Documents:	Title Acronym: Other Ids: •NIDA-09262-13 •P50DA009262 •DPMCDA	Recruiting	•Cocaine Abuse •Cocaine Dependence •Opiate Dependence •Alcohol Dependence •Substance Abuse	•Drug: modafinil •Drug: d-amphetamine •Drug: L-Dopa •Drug: Naltrexone	Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Prospective Outcome Measures: •Urine Toxicology •Demographics	Enrollment: 7500 Age: 18 Years to 60 Years (Adult) Sex: All	•The University of Texas Health Science Center, Houston •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: October 2005 Primary Completion: June 2021 Study Completion: June 2021 First Posted: February 22, 2007 Results First Posted: No Results Posted Last Update Posted: November 1, 2018	•University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas, United States
54	NCT01890785	Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers Study Documents:	Title Acronym: Other Ids: SPD489-123	Completed	•Healthy Volunteers	•Drug: Lisdexamfetamine Dimesylate	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate •Maximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate •AUC for D-amphetamine •Cmax for D-amphetamine	Enrollment: 30 Age: 18 Years to 55 Years (Adult) Sex: All	•Shire	•Industry	Study Start: July 15, 2013 Primary Completion: August 22, 2013 Study Completion: August 22, 2013 First Posted: July 2, 2013 Results First Posted: April 21, 2014 Last Update Posted: January 8, 2019	•Clinical Pharmacology of Miami, Inc, Miami, Florida, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
55	NCT00247572	Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Study Documents:	Title Acronym: Other Ids: •NRP104.A02 •WIRB(R) Protocol #20051316	Completed	•Attention Deficit Disorder With Hyperactivity •Amphetamine-Related Disorders •Substance-Related Disorders	•Drug: NRP104	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •Pharmacodynamic (PD) Parameters: •The following parameters will be measured at fixed time intervals post drug and used to compare the •effects of various doses of NRP104 with placebo and d-amphetamine sulfate for pharmacodynamic •equivalence: •(1) Maximum liking scale scores for euphoria measured by DRQS and DRQO •(2) Maximum disliking scale scores for dysphoria measured by DRQS and DRQO •(3) Maximum scores on the MBG, BG and Amphetamine scales of the ARCI •(4) Maximum supine systolic and diastolic blood pressure changes from baseline •(5) Maximum orthostatic pulse increases from baseline •(6) Spontaneous reports of discomforting subjective effects •and 9 more	Enrollment: 12 Age: 18 Years to 55 Years (Adult) Sex: All	•New River Pharmaceuticals	•Industry	Study Start: September 2005 Primary Completion: Study Completion: November 2005 First Posted: November 2, 2005 Results First Posted: No Results Posted Last Update Posted: November 5, 2007	•Johns Hopkins Bayview Medical Center, Clinical Studies Program, Baltimore, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
56	NCT03397446	Lisdexamfetamine for Adults With Bulimia Nervosa Study Documents:	Title Acronym: Other Ids: LDXBN	Recruiting	•Bulimia Nervosa	•Drug: Lisdexamfetamine dimesylate	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Enrolment rate •Dropout rates •The applicability of eligibility criteria •Incidence of serious or other treatment-emergent adverse events (TEAEs) •Change from baseline in weight/body mass index •Change from baseline in systolic/diastolic blood pressure (mmHg) •Change from baseline in heart rate (bpm) •Incidence of abnormal adherence rates •Incidence of abnormalities in blood analysis •Incidence of abnormalities in EKG •and 17 more	Enrollment: 30 Age: 18 Years to 55 Years (Adult) Sex: All	•Aaron Keshen •Nova Scotia Health Authority	•Other	Study Start: June 21, 2018 Primary Completion: December 2019 Study Completion: November 2020 First Posted: January 12, 2018 Results First Posted: No Results Posted Last Update Posted: June 25, 2018	•Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
57	NCT01486810	Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence Study Documents:	Title Acronym: Vyvance Other Ids: •#6154 •P50DA009236-18	Completed	•Cocaine Dependence	•Drug: Lisdexamfetamine •Behavioral: medication management	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose. •Mean Maximum Maintained Dose of Lisdexamfetamine for at Least 1 Week of Trial.	Enrollment: 17 Age: 18 Years to 60 Years (Adult) Sex: All	•New York State Psychiatric Institute •National Institute on Drug Abuse (NIDA)	•Other •NIH	Study Start: December 2011 Primary Completion: December 2013 Study Completion: December 2013 First Posted: December 7, 2011 Results First Posted: July 11, 2018 Last Update Posted: November 1, 2018	•STARS, New York, New York, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
58	NCT00746733	Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Study Documents:	Title Acronym: Other Ids: SPD489-113	Completed	•Healthy Volunteers	•Drug: Lisdexamfetamine Dimesylate •Drug: Adderall XR (mixed salts amphetamine)	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) Outcome Measures: •Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC •Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC •Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC •Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC •Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC •Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC •AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC •T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC •Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC •Tmax of Total	Enrollment: 24 Age: 18 Years to 45 Years (Adult) Sex: All	•Shire	•Industry	Study Start: September 2008 Primary Completion: October 2008 Study Completion: October 2008 First Posted: September 4, 2008 Results First Posted: November 17, 2009 Last Update Posted: November 20, 2009	•Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
59	NCT02210728	Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder Study Documents:	Title Acronym: Other Ids: PED-06-002	Active, not recruiting	•Attention Deficit Hyperactivity Disorder	•Drug: methylphenidate or amphetamine product •Behavioral: Cognitive behavioral therapy	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Self-reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale) - Change from baseline •Self-reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale) •Global psychological distress (measured via the Symptom Checklist 90) - Change from baseline •Depression symptoms (via the Beck Depression Inventory) - Change from baseline •Anxiety symptoms (measured via the Beck Anxiety Inventory) - Change from baseline •Global functional impairment (measured via the Sheehan Disability Scale) - Change from baseline •Dyadic adjustment (for those married or cohabiting, measured via the Dyadic Adjustment Scale) - Change from baseline •Organizational skills (measured via the Organization and Activation for Work Scale) - Change from baseline •Self-esteem (measured via the Index of Self-Esteem) - Change from baseline •Anger Expression (measured via the State Trait Anger Expression Inventory - II) - Change from baseline	Enrollment: 200 Age: 18 Years to 60 Years (Adult) Sex: All	•Lily Hechtman •McGill University Health Center	•Other	Study Start: April 2006 Primary Completion: October 2018 Study Completion: October 2018 First Posted: August 7, 2014 Results First Posted: No Results Posted Last Update Posted: August 28, 2018	•Montreal Children's Hospital, Montreal, Quebec, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
60	NCT01263548	To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder Study Documents:	Title Acronym: Other Ids: Vyvanse-BD	Completed	•Attention Deficit/ Hyperactivity Disorder •Bipolar Disorder	•Drug: lisdexamfetamine dimesylate	Study Type: Observational Phase: Study Design: Time Perspective: Prospective Outcome Measures: •Metabolic parameters •ADHD-RS •CAARS •CGI-BP •Q-LES-Q •AAQoL •Metabolic Peptidergic systems	Enrollment: 45 Age: 18 Years to 55 Years (Adult) Sex: All	•University Health Network, Toronto •Shire	•Other •Industry	Study Start: October 2010 Primary Completion: January 2012 Study Completion: January 2012 First Posted: December 20, 2010 Results First Posted: No Results Posted Last Update Posted: June 1, 2012	•Mood Disorders Psychopharmacology Unit, Toronto, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
61	NCT00248092	Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Study Documents:	Title Acronym: Other Ids: NRP104.A03	Completed	•Attention Deficit Disorder With Hyperactivity •Amphetamine-Related Disorders •Substance-Related Disorders	•Drug: NRP104	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •The difference in the time to maximum change from baseline in the Liking scale score (Question 2) from the Drug Rating Questionnaire - Subject (DRQS). •Maximum Liking score (Question 2 from DRQS) change from baseline •Question 1 and 3 from the DRQS •Question 1, 2 and 3 from the Drug Rating Questionnaire- Observer (DRQO) •Subscale of the ARCI (MBG, Amphetamine, BG, LSD and PCAG) (subject) •Street Value assessment Questionnaire (subject) •Treatment Enjoyment assessment Questionnaire (TEAQ) (subject) •Safety •Adverse events, laboratory tests, physical examination, vital signs and ECG will be collected to •assess the safety and tolerability of NRP104.	Enrollment: 36 Age: 18 Years to 55 Years (Adult) Sex: All	•New River Pharmaceuticals	•Industry	Study Start: January 2006 Primary Completion: Study Completion: May 2006 First Posted: November 3, 2005 Results First Posted: No Results Posted Last Update Posted: November 5, 2007	•Johns Hopkins Bayview Medical Center, Clinical Studies Program, Baltimore, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
62	NCT00228046	Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Study Documents:	Title Acronym: Other Ids: •K23MH064975 •M01RR010710 •DSIR CT-M1	Completed	•Attention Deficit Disorder With Hyperactivity •Conduct Disorder •Oppositional Defiant Disorder	•Drug: Divalproex Sodium •Drug: Methylphenidate •Drug: Dextroamphetamine •Drug: Mixed Amphetamine Salts •Behavioral: Family Counseling •Behavioral: Behavior Management Training with Parents	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •Aggression (Measured by the Overt Aggression Scale after 8 weeks of treatment) •Improvement of ADHD symptoms (Measured by the Clinical Global Improvement Scale and ADHD Rating Scale after 8 weeks of treatment)	Enrollment: 40 Age: 6 Years to 14 Years (Child) Sex: All	•Stony Brook University •National Institute of Mental Health (NIMH)	•Other •NIH	Study Start: January 2004 Primary Completion: July 2007 Study Completion: July 2007 First Posted: September 28, 2005 Results First Posted: No Results Posted Last Update Posted: October 31, 2013	•Long Island Jewish Medical Center / Schneider Children's Hospital, New Hyde Park, New York, United States •Stony Brook University Hospital, Stony Brook, New York, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
63	NCT02788851	The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Study Documents:	Title Acronym: Other Ids: MUHC-15-226	Active, not recruiting	• Attention Deficit Hyperactivity Disorder (ADHD)	• Drug: Methylphenidate compounds and / or Amphetamine compounds and/ or Strattera or Guanfacine • Behavioral: Aerobic Exercise	Study Type: Interventional Phase: Not Applicable Study Design: • Allocation: Randomized • Intervention Model: Parallel Assignment • Masking: None (Open Label) • Primary Purpose: Treatment Outcome Measures: • Self-reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale) - Change from baseline • Depression symptoms (via the Beck Depression Inventory) - Change from baseline • Anxiety Symptoms (measured via the Beck Anxiety Inventory) - Change from baseline • Global functional impairment (measured via the Sheehan Disability Scale) - Change from baseline • Self-esteem (measured via the Index of Self-Esteem) - Change from baseline • Dyadic adjustment (for those married or cohabiting, measured via the Dyadic Adjustment Scale) - Change from baseline • Motivation to exercise (measured via the Physical Activity and Leisure Motivation Scale) - Change from baseline • Stimulant medication side effects (measured via the Canadian ADHD Resource Alliance (CADDRA) Patient ADHD Medication Form)	Enrollment: 70 Age: 18 Years to 60 Years (Adult) Sex: All	• McGill University Health Center	• Other	Study Start: April 2016 Primary Completion: December 2018 Study Completion: December 2018 First Posted: June 2, 2016 Results First Posted: No Results Posted Last Update Posted: August 15, 2018	• Montreal Children's Hospital, Montreal, Quebec, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
64	NCT00865332	Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates Study Documents:	Title Acronym: Other Ids: •080437 •08-DA-0437	Withdrawn	•Cocaine Addiction •Cocaine Abuse		Study Type: Observational Phase: Study Design: Outcome Measures:	Enrollment: 0 Age: 18 Years to 50 Years (Adult) Sex: All	•National Institute on Drug Abuse (NIDA) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: December 12, 2007 Primary Completion: Study Completion: December 21, 2010 First Posted: March 19, 2009 Results First Posted: No Results Posted Last Update Posted: July 2, 2017	•National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States •National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
65	NCT01913912	Event Rate and Effects of Stimulants in ADHD Study Documents:	Title Acronym: ERESA Other Ids: •EC/2013/481 •2013-001530-18	Unknown status	•Attention Deficit Hyperactivity Disorder	•Drug: LDX. •Drug: sugar pill •Device: computer task (Go/No-Go task) •Device: EEG •Device: pupil size measurements (by using eye tracking)	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) Outcome Measures: •Performance data (by using computerized Go-No Go task) •psychophysiological data	Enrollment: 25 Age: 7 Years to 12 Years (Child) Sex: All	•University Ghent •Fund for Scientific Research, Flanders, Belgium •Shire	•Other •Industry	Study Start: January 2015 Primary Completion: December 2015 Study Completion: December 2015 First Posted: August 1, 2013 Results First Posted: No Results Posted Last Update Posted: December 5, 2014	•Ghent University Hospital, Ghent, Belgium •Ghent University Hospital, Ghent, Belgium •Ghent University, Ghent, Belgium

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
66	NCT02033707	Effects of Hallucinogens and Other Drugs on Mood and Performance Study Documents:	Title Acronym: Other Ids: NA_00082804	Active, not recruiting	•Healthy	•Drug: Hallucinogens and psychoactive substances	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: •Rating of "Drug Liking" on the End of Day Questionnaire •Hallucinogen Rating Scale	Enrollment: 20 Age: 21 Years to 50 Years (Adult) Sex: All	•Johns Hopkins University	•Other	Study Start: April 2014 Primary Completion: January 2019 Study Completion: January 2020 First Posted: January 13, 2014 Results First Posted: No Results Posted Last Update Posted: December 7, 2018	•Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
67	NCT02566824	Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Study Documents:	Title Acronym: Other Ids: PED-05-055	Recruiting	• Attention Deficit Hyperactivity Disorder	• Behavioral: Cognitive Behavioural & Skills Training • Behavioral: Supportive Group Therapy • Other: Treatment as Usual - community resources • Drug: Methylphenidate or amphetamine product	Study Type: Interventional Phase: Phase 4 Study Design: • Allocation: Randomized • Intervention Model: Parallel Assignment • Masking: Single (Outcomes Assessor) • Primary Purpose: Treatment Outcome Measures: • Attention Deficit/ Hyperactivity Disorder (ADHD) Symptomatology (measured via Conners' 3 Adolescent Self-Report Scale short form; Conners' 3 parent version; Conners' 3 teacher version) - Change from baseline • Organizational skills (measured via Children's Organizational Skills Scale (COSS) completed by adolescent and parent) - Change from baseline • Emotional adjustment - (including ODD, conduct disorder symptoms, depression, and anxiety) measured via Stony Brook Child and Adolescent Symptom Inventory - 5 (CASI-5) completed by adolescent and parent - Change from baseline • Self-esteem - evaluated via Rosenberg Self Esteem Scale (RSES) completed by the adolescent - Change from baseline • Social skills measured via Social Skills Improvement System (SSIS) completed by adolescent and parent - Change from baseline • Parent-adolescent conflict measured via the Parent Issues Checklist- Revised completed by the parent - Change from baseline	Enrollment: 216 Age: 13 Years to 17 Years (Child) Sex: All	• McGill University Health Center • Canadian Institutes of Health Research (CIHR)	• Other	Study Start: October 2010 Primary Completion: August 2020 Study Completion: October 2020 First Posted: October 2, 2015 Results First Posted: No Results Posted Last Update Posted: July 31, 2018	• Montreal Children's Hospital, Montreal, Quebec, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
68	NCT01399827	Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits Study Documents: • Study Protocol and Statistical Analysis Plan	Title Acronym: Other Ids: 2010-P-002435	Completed	• Attention Deficit Hyperactivity Disorder (ADHD) • Deficient Emotional Self-Regulation (DESR)	• Drug: ADHD Medication • Drug: Omega-3 Fatty Acids	Study Type: Interventional Phase: Phase 2 Study Design: • Allocation: Randomized • Intervention Model: Parallel Assignment • Masking: Triple (Participant, Investigator, Outcomes Assessor) • Primary Purpose: Treatment Outcome Measures: • Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale • Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score • Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale • Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales • Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale	Enrollment: 2 Age: 18 Years to 55 Years (Adult) Sex: All	• Massachusetts General Hospital	• Other	Study Start: February 2012 Primary Completion: November 2017 Study Completion: November 2017 First Posted: July 22, 2011 Results First Posted: October 23, 2018 Last Update Posted: October 23, 2018	• Massachusetts General Hospital, Boston, Massachusetts, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
69	NCT00047866	Brain Function in Response to Motivational Stimuli Study Documents:	Title Acronym: Other Ids: •030013 •03-AA-0013	Completed	•Drug Dependence		Study Type: Observational Phase: Study Design: Outcome Measures:	Enrollment: 38 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•National Institute on Alcohol Abuse and Alcoholism (NIAAA) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: October 12, 2002 Primary Completion: Study Completion: June 25, 2010 First Posted: October 23, 2002 Results First Posted: No Results Posted Last Update Posted: July 2, 2017	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
70	NCT00919867	A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers Study Documents:	Title Acronym: Other Ids: SPD503-115	Completed	•Healthy	•Drug: SPD503 •Drug: VYVANSE •Drug: SPD503 and VYVANSE	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) Outcome Measures: •Maximum Plasma Concentration (Cmax) of Guanfacine •Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine •Time of Maximum Plasma Concentration (Tmax) of Guanfacine •Time of Plasma Half-Life(T 1/2) of Guanfacine •Cmax of d-Amphetamine •AUC of d-Amphetamine •Tmax of d-Amphetamine •T 1/2 of d-Amphetamine	Enrollment: 42 Age: 18 Years to 45 Years (Adult) Sex: All	•Shire	•Industry	Study Start: July 2009 Primary Completion: August 2009 Study Completion: August 2009 First Posted: June 12, 2009 Results First Posted: August 2, 2010 Last Update Posted: February 6, 2014	•Advanced Biomedical Research, Inc., Hackensack, New Jersey, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
71	NCT02204410	Omega-3 Supplementation to ADHD Medication in Children Study Documents:	Title Acronym: Other Ids: 2014-P-000015	Completed	•Attention Deficit Hyperactivity Disorder •Deficient Emotional Self-Regulation	•Dietary Supplement: Omega-3 Fatty Acid •Drug: ADHD Medication	Study Type: Interventional Phase: Phase 4 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent) •Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)	Enrollment: 21 Age: 6 Years to 17 Years (Child) Sex: All	•Massachusetts General Hospital	•Other	Study Start: July 2014 Primary Completion: May 2016 Study Completion: August 2016 First Posted: July 30, 2014 Results First Posted: June 29, 2017 Last Update Posted: June 29, 2017	•Massachusetts General Hospital, Boston, Massachusetts, United States